Forte Biosciences, Inc. FBRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-6.85
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$69.4M | — | -$51.0M | $61.0M |
| 2024 | — | -$35.5M | — | -$30.8M | $52.5M |
| 2023 | — | -$31.5M | — | -$28.8M | $35.3M |
| 2022 | — | -$13.9M | — | — | $38.8M |
| 2021 | — | -$21.7M | — | — | $41.5M |
| 2020 | — | -$46.5M | — | — | $59.0M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -6.85 (distress)
- Working capital / assets 0.723
- Retained earnings / assets -2.698
- EBIT / assets -0.854
- Equity / liabilities 2.799
Source: SEC EDGAR filings · CIK 0001419041 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.